147254-64-6,MFCD00920915
Catalog No.:AA00ABIR

147254-64-6 | Ranirestat

Pack Size
Purity
Availability
Price(USD)
Quantity
  
5mg
96%
1 week  
$373.00   $261.00
- +
10mg
96%
1 week  
$565.00   $395.00
- +
25mg
96%
1 week  
$1,130.00   $791.00
- +
50mg
96%
1 week  
$1,777.00   $1,244.00
- +
100mg
96%
1 week  
$2,812.00   $1,969.00
- +
  • Technical Information
  • Properties
  • Literature
  • Request for Quotation
  • Download SDS
Technical Information
Catalog Number:
AA00ABIR
Chemical Name:
Ranirestat
CAS Number:
147254-64-6
Molecular Formula:
C17H11BrFN3O4
Molecular Weight:
420.1893
MDL Number:
MFCD00920915
SMILES:
O=C1NC(=O)[C@]2(C1)C(=O)N(Cc1ccc(cc1F)Br)C(=O)c1n2ccc1
Properties
Computed Properties
 
Complexity:
689  
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
1  
Defined Bond Stereocenter Count:
0  
Formal Charge:
0  
Heavy Atom Count:
26  
Hydrogen Bond Acceptor Count:
5  
Hydrogen Bond Donor Count:
1  
Isotope Atom Count:
0  
Rotatable Bond Count:
2  
Undefined Atom Stereocenter Count:
0  
Undefined Bond Stereocenter Count:
0  
XLogP3:
1.3  

Literature

Title: A concise enantioselective synthesis of (-)-ranirestat.

Journal: Organic letters 20100319

Title: Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review.

Journal: Journal of diabetes and its complications 20100101

Title: Inventing and understanding catalytic, enantioselective reactions.

Journal: Current opinion in drug discovery & development 20091101

Title: Ranirestat for the management of diabetic sensorimotor polyneuropathy.

Journal: Diabetes care 20090701

Title: Improvement of motor nerve conduction velocity in diabetic rats requires normalization of the polyol pathway metabolites flux.

Journal: Journal of pharmacological sciences 20090201

Title: An improved lanthanum catalyst system for asymmetric amination: toward a practical asymmetric synthesis of AS-3201 (Ranirestat).

Journal: Organic letters 20080703

Title: Long-term treatment with ranirestat (AS-3201), a potent aldose reductase inhibitor, suppresses diabetic neuropathy and cataract formation in rats.

Journal: Journal of pharmacological sciences 20080701

Title: Ranirestat (AS-3201), a potent aldose reductase inhibitor, reduces sorbitol levels and improves motor nerve conduction velocity in streptozotocin-diabetic rats.

Journal: Journal of pharmacological sciences 20080701

Title: Stability and hydrolysis kinetics of spirosuccinimide type inhibitors of aldose reductase in aqueous solution and retardation of their hydrolysis by the target enzyme.

Journal: Journal of pharmaceutical sciences 20080401

Title: Ranirestat as a therapeutic aldose reductase inhibitor for diabetic complications.

Journal: Expert opinion on investigational drugs 20080401

Title: Stereospecific recognition of a spirosuccinimide type aldose reductase inhibitor (AS-3201) by plasma proteins: a significant role of specific binding by serum albumin in the improved potency and stability.

Journal: Biochemical pharmacology 20060112

Title: Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy.

Journal: Diabetes care 20060101

Title: [Role of polyol pathway in pathogenesis of diabetic microangiopathy].

Journal: Nihon rinsho. Japanese journal of clinical medicine 20050601

Title: [Progress on the drug therapy for diabetic microangiopathies: aldose reductase inhibitor].

Journal: Nihon rinsho. Japanese journal of clinical medicine 20050601

Title: Aldose reductase inhibition by AS-3201 in sural nerve from patients with diabetic sensorimotor polyneuropathy.

Journal: Diabetes care 20041001

Title: Uridine diphosphate sugar-selective conjugation of an aldose reductase inhibitor (AS-3201) by UDP-glucuronosyltransferase 2B subfamily in human liver microsomes.

Journal: Biochemical pharmacology 20040401

Title: Stereospecific interaction of a novel spirosuccinimide type aldose reductase inhibitor, AS-3201, with aldose reductase.

Journal: Biochemistry 20010727

Title: Matsumoto T, et al. Improvement of motor nerve conduction velocity in diabetic rats requires normalization of the polyol pathway metabolites flux. J Pharmacol Sci. 2009 Feb;109(2):203-10.

Title: Toyoda F, et al. Effect of ranirestat, a new aldose reductase inhibitor, on diabetic retinopathy in SDT rats. J Diabetes Res. 2014;2014:672590.

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Related Products of 147254-64-6
Historical Records
Tags:147254-64-6 Molecular Formula|147254-64-6 MDL|147254-64-6 SMILES|147254-64-6 Ranirestat
Catalog No.: AA00ABIR
147254-64-6,MFCD00920915
147254-64-6 | Ranirestat
Pack Size: 5mg
Purity: 96%
1 week
$373.00 $261.00
Pack Size: 10mg
Purity: 96%
1 week
$565.00 $395.00
Pack Size: 25mg
Purity: 96%
1 week
$1,130.00 $791.00
Pack Size: 50mg
Purity: 96%
1 week
$1,777.00 $1,244.00
Pack Size: 100mg
Purity: 96%
1 week
$2,812.00 $1,969.00
Quantity
- +
Add to Card
Order Now
bulk Quotation Request
Technical Information
Catalog Number: AA00ABIR
Chemical Name: Ranirestat
CAS Number: 147254-64-6
Molecular Formula: C17H11BrFN3O4
Molecular Weight: 420.1893
MDL Number: MFCD00920915
SMILES: O=C1NC(=O)[C@]2(C1)C(=O)N(Cc1ccc(cc1F)Br)C(=O)c1n2ccc1
Properties
Complexity: 689  
Covalently-Bonded Unit Count: 1  
Defined Atom Stereocenter Count: 1  
Defined Bond Stereocenter Count: 0  
Formal Charge: 0  
Heavy Atom Count: 26  
Hydrogen Bond Acceptor Count: 5  
Hydrogen Bond Donor Count: 1  
Isotope Atom Count: 0  
Rotatable Bond Count: 2  
Undefined Atom Stereocenter Count: 0  
Undefined Bond Stereocenter Count: 0  
XLogP3: 1.3  
Literature fold

Title: A concise enantioselective synthesis of (-)-ranirestat.

Journal: Organic letters20100319

Title: Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review.

Journal: Journal of diabetes and its complications20100101

Title: Inventing and understanding catalytic, enantioselective reactions.

Journal: Current opinion in drug discovery & development20091101

Title: Ranirestat for the management of diabetic sensorimotor polyneuropathy.

Journal: Diabetes care20090701

Title: Improvement of motor nerve conduction velocity in diabetic rats requires normalization of the polyol pathway metabolites flux.

Journal: Journal of pharmacological sciences20090201

Title: An improved lanthanum catalyst system for asymmetric amination: toward a practical asymmetric synthesis of AS-3201 (Ranirestat).

Journal: Organic letters20080703

Title: Long-term treatment with ranirestat (AS-3201), a potent aldose reductase inhibitor, suppresses diabetic neuropathy and cataract formation in rats.

Journal: Journal of pharmacological sciences20080701

Title: Ranirestat (AS-3201), a potent aldose reductase inhibitor, reduces sorbitol levels and improves motor nerve conduction velocity in streptozotocin-diabetic rats.

Journal: Journal of pharmacological sciences20080701

Title: Stability and hydrolysis kinetics of spirosuccinimide type inhibitors of aldose reductase in aqueous solution and retardation of their hydrolysis by the target enzyme.

Journal: Journal of pharmaceutical sciences20080401

Title: Ranirestat as a therapeutic aldose reductase inhibitor for diabetic complications.

Journal: Expert opinion on investigational drugs20080401

Title: Stereospecific recognition of a spirosuccinimide type aldose reductase inhibitor (AS-3201) by plasma proteins: a significant role of specific binding by serum albumin in the improved potency and stability.

Journal: Biochemical pharmacology20060112

Title: Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy.

Journal: Diabetes care20060101

Title: [Role of polyol pathway in pathogenesis of diabetic microangiopathy].

Journal: Nihon rinsho. Japanese journal of clinical medicine20050601

Title: [Progress on the drug therapy for diabetic microangiopathies: aldose reductase inhibitor].

Journal: Nihon rinsho. Japanese journal of clinical medicine20050601

Title: Aldose reductase inhibition by AS-3201 in sural nerve from patients with diabetic sensorimotor polyneuropathy.

Journal: Diabetes care20041001

Title: Uridine diphosphate sugar-selective conjugation of an aldose reductase inhibitor (AS-3201) by UDP-glucuronosyltransferase 2B subfamily in human liver microsomes.

Journal: Biochemical pharmacology20040401

Title: Stereospecific interaction of a novel spirosuccinimide type aldose reductase inhibitor, AS-3201, with aldose reductase.

Journal: Biochemistry20010727

Title: Matsumoto T, et al. Improvement of motor nerve conduction velocity in diabetic rats requires normalization of the polyol pathway metabolites flux. J Pharmacol Sci. 2009 Feb;109(2):203-10.

Title: Toyoda F, et al. Effect of ranirestat, a new aldose reductase inhibitor, on diabetic retinopathy in SDT rats. J Diabetes Res. 2014;2014:672590.

Building Blocks More >
1883429-22-8
1883429-22-8
Bi-9564
AA00ABOC | MFCD30182324
19179-60-3
19179-60-3
Methyl 2,2-diphenylcyclopropanecarboxylate
AA00ABTV | MFCD00543344
171596-41-1
171596-41-1
(1R,3R)-METHYL-1,2,3,4-TETRAHYDRO-1-(3,4-METHYLENEDIOXYPHENYL)-9H-PYRIDO[3,4-B]INDOLE-3-CARBOXYLATE
AA00ABX1 | MFCD04973634
15266-88-3
15266-88-3
Cyclo(-gly-his)
AA00ACEQ | MFCD00237614
19614-15-4
19614-15-4
Ethyl 4-morpholinobenzenecarboxylate
AA00ACST | MFCD06204958
153715-08-3
153715-08-3
9,10-Bis(3,5-dihydroxyphenyl)anthracene
AA00ACZD | MFCD03427350
199191-66-7
199191-66-7
(S)-Duloxetine SuccinaMide
AA00AD5V | MFCD27965891
149790-22-7
149790-22-7
Tris[2-(perfluorooctyl)ethyl] Phosphate
AA00ADD4 | MFCD19440707
1486466-31-2
1486466-31-2
(17R)-4'-Chloro-5'-ethyl-9-fluoro-11β-hydroxy-16β-Methylspiro[androsta-1,4-diene-17,2'(3'H)-furan]-3,3'-dione
AA00ADIR | MFCD11558988
1838-41-1
1838-41-1
Tetramethylammonium dichloroiodate(i)
AA00ADS3 | MFCD00800939
Submit
© 2017 AA BLOCKS, INC. All rights reserved.